Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does mycophenolate mofetil reduce the risk of late acute rejection after liver transplantation?

Nature Clinical Practice Gastroenterology & Hepatology volume 3, pages 664–665 (2006)Cite this article

boxed-textWiesner RH et al. (2006) Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplantation. Am J Transplant 6: 1609–1616

Triple-drug immunosuppression regimens including mycophenolate mofetil, taken for ≥6 months are associated with reduced rates of LAR; further studies are needed to define optimal immunosuppression

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ramji A et al. (2002) Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl 8: 945–951

    Article  Google Scholar 

  2. Anand A et al. (1995) Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 60: 1098–1103

    Article  CAS  Google Scholar 

  3. Lake J et al. (2005) Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. Am J Transplant 5: 2961–2967

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Clinical Transplant Fellow Capital Health and the University of Alberta, Edmonton, AB, Canada

    Christian Toso

  2. Director of Transplantation and of the Liver Transplant Program at Capital Health and the University of Alberta, Edmonton, AB, Canada

    Norman Kneteman

Authors
  1. Christian Toso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norman Kneteman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norman Kneteman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toso, C., Kneteman, N. Does mycophenolate mofetil reduce the risk of late acute rejection after liver transplantation?. Nat Rev Gastroenterol Hepatol 3, 664–665 (2006). https://doi.org/10.1038/ncpgasthep0662

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0662

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing